Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Alzheimer's Disease
Trial Information
Evaluation of a investigational oral medication for patients with Alzheimer’s Disease.
A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve- Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil.
This is a one-year study with a one in three chance of receiving placebo. All patients will have the opportunity to receive the study medication at the end of the one year blinded portion.
Major Inclusion/Exclusion Criteria:
- Age greater or equal to 50 years old
- Must be taking Aricept 10 mg for a minimum of six months
- Must be off all other Alzheimer’s medications for 90 days prior to screening
- Must have a caregiver for a minimum of three hours a day five days a week
- History of Insulin-dependent Diabetes is excluded
- History of cancer within the past five years is excluded (except for skin and prostate cancer)
Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304
Phone: 303.443.7229 ext 107
EMail: anita@alpineresearch.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
